1. Home
  2. ROMA vs LGVN Comparison

ROMA vs LGVN Comparison

Compare ROMA & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roma Green Finance Limited

ROMA

Roma Green Finance Limited

HOLD

Current Price

$7.61

Market Cap

503.9M

Sector

Finance

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.85

Market Cap

34.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROMA
LGVN
Founded
2018
2014
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Savings Institutions
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.9M
34.0M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ROMA
LGVN
Price
$7.61
$0.85
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
35.1K
367.9K
Earning Date
12-23-2025
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
N/A
$709,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.16
$0.48
52 Week High
$11.77
$1.80

Technical Indicators

Market Signals
Indicator
ROMA
LGVN
Relative Strength Index (RSI) 56.72 47.89
Support Level $2.05 $0.74
Resistance Level $8.68 $0.86
Average True Range (ATR) 0.68 0.06
MACD -0.02 -0.00
Stochastic Oscillator 65.77 62.76

Price Performance

Historical Comparison
ROMA
LGVN

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: